found that ovarian cancer patients treated with the IDO1 inhibitor Epacadostat experienced a shift in internal tumor tryptophan metabolism toward the NAD+ synthesis pathway, which also affected T cell infiltration and anti-tumor immune function. Here, IDO1 is linked to ovarian cancer.